Yüklüyor......
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
BACKGROUND/AIMS: Data on the efficacy and safety of the adalimumab biosimilar Exemptia are limited. METHODS: Patients with moderate-to-severe active steroid-refractory ulcerative colitis (UC) treated at Dayanand Medical College and Hospital, India were offered cyclosporine A, biologicals or biosimil...
Kaydedildi:
| Yayımlandı: | Intest Res |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Korean Association for the Study of Intestinal Diseases
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5797276/ https://ncbi.nlm.nih.gov/pubmed/29422802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2018.16.1.83 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|